With no preventive intervention currently available, aging and nearsighted vision problems are considered the major risk factors for Symptomatic Vitreomacular Adhesion (VMA), caused by an incomplete posterior vitreous separation from the retina located at the back of the eye. If left unresolved, these areas of vitreomacular adhesion can extert a “pulling force” on the macula. In Europe alone there are over 800,000 people who suffer from VMA and the diagnoses are expected to increase due to the widespread use of optical coherence tomography (OCT) which has allowed more accurate criteria in VMA management and classification.
After recent approval of the first pharmacologic option to resolve VMA, including when associated with a macular hole, clinicians are tasked to determine how to best incorporate it into their practices. The Epiomic™ database is able to give a clear understanding into the number of patients most likely to benefit, segmenting VMA by eye location, detachment width and clinical presentations. It will also certainly be invaluable for the users in gaining a deep understanding of the types of multiple co-morbidities that can cause impaired quality of life and vision loss if not treated rapidly.
Did you know ... Patients with exudative age-related macular degeneration (AMD) are 59% more likely to have VMA, compared with 13% in eyes with non exudative AMD.